Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Learnings from a CAR-T center: leukapheresis, bridging therapy, toxicities & more

Michael von Bergwelt • 15 Mar 2019
ISAL 2019
General Leukemia Lymphoma CAR-T Tocilizumab

Michael von Bergwelt, MD, PhD, of LMU Hospital Munich, Munich, Germany, discusses the considerations when giving CAR-T in the clinic, including reimbursement, preparing the patient, determining a bridging therapy, toxicity control and more. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

More from Michael von Bergwelt

2:25
Increase in cancer patient transfers to the ICU: what does it come down to?
Michael von Bergwelt • 10 Jul 2019
2:33
EuroCARTForce: a platform for progress
Michael von Bergwelt • 10 Jul 2019
1:14
Preparing the critical care workforce for CAR-T
Michael von Bergwelt • 10 Jul 2019
2:30
Intensive care for CAR-T: bridge to treatment and response
Michael von Bergwelt • 15 Mar 2019

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
The content of VJHemOnc is intended for healthcare professionals